When a doctor receives an alert from the ANSM about a poorly traced defibrillator, or when an ethics committee from the WHO publishes new rules to regulate research in artificial intelligence, these decisions concretely change medical practice. Several recent advancements in health news deserve our attention, not for their spectacular nature, but because they alter the rules of the game for both professionals and patients.
Medical Devices in France: ANSM Tightens Control Over Distribution
We often talk about the compliance of medical device manufacturers. We talk less about what happens after manufacturing, that is, with distributors, importers, and maintenance providers.
In September 2026, the ANSM published several injunctions targeting companies that distribute or import devices such as defibrillators. The identified shortcomings do not concern the product design, but traceability, maintenance, and complaint management. In other words, a device can be compliant when it leaves the factory but become a risk if its post-marketing follow-up is deficient.
The European regulation 2017/745 imposes specific obligations on each link in the chain. Checking compliance, ensuring vigilance, documenting incidents: these requirements now apply with the same rigor to distributors as to manufacturers. Compliance no longer stops at the factory gate.
To keep track of these regulatory developments over the weeks, health news on Santé Info provides an overview of the decisions that directly impact medical practice in France.
Medical Research and Artificial Intelligence: WHO Establishes a Concrete Ethical Framework
You may have noticed that most articles on AI in health talk about promises (faster diagnosis, personalized treatment), but rarely about safeguards? The WHO has just filled this gap.
On September 21, 2026, the World Health Organization published a report titled Artificial Intelligence-related health research: ethics review and oversight. The title is technical, but the content is very concrete: it aims to define how ethics committees should evaluate research projects that use AI.
Until now, the reflection was on medical AI in general, with broad principles (transparency, fairness, respect for privacy). This report marks a shift in focus. It moves from a statement of intent to governance requirements that can be directly applied by research institutions.
What This Changes for a Research Project
A researcher developing an algorithm for detecting skin lesions, for example, will now have to submit their protocol for an ethical review that takes into account the specifics of AI. Bias in training data, reproducibility of results, consent from patients whose data feed the model: these are all points that become formal evaluation criteria.
The ethical framework for AI in health moves from principle to procedure. It’s less spectacular than an announcement about a surgical robot, but it’s this type of framework that determines whether an innovation is reliably adopted or abandoned due to lack of trust.
Pandemic Preparedness: An International Architecture Under Construction
After the Covid-19 crisis, the question was not whether to prepare better, but how. Several years of negotiations have led to concrete advancements in 2026.
The WHO is working on two parallel tracks:
- The adoption of an International Agreement on pandemics, aimed at coordinating states’ responses in the event of a new global health threat.
- The strengthening of the International Health Regulations, the legal text that already governs the surveillance and notification of public health emergencies.
- An effort to consolidate national public health institutions, with commitments made by several countries during the United Nations General Assembly in September 2026.
Why do these negotiations matter beyond diplomatic circles? Because they determine, for example, whether a country will be able to quickly access vaccines or treatments during the next epidemic, or whether it will have to wait until better-equipped countries have been served first.
A Matter of Solidarity as Much as Security
The WHO emphasized in September 2026 that pressures on health systems are not easing. Investing in pandemic preparedness also means investing in more resilient health systems capable of facing a dengue outbreak in summer just as much as a flu wave in winter.
Pharmacovigilance and Access to Medicines: Decisions to Monitor Closely
The ANSM made several decisions in September 2026 regarding access to certain treatments and the monitoring of drugs already on the market. These decisions, often lost in the news flow, determine which drugs will be available, under what conditions, and with what level of oversight. They deserve regular attention from healthcare professionals as well as concerned patients.
